Two Seas Capital LP Invests $7.99 Million in Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Two Seas Capital LP purchased a new stake in shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 14,835,146 shares of the biotechnology company's stock, valued at approximately $7,992,000. Adaptimmune Therapeutics makes up about 0.6% of Two Seas Capital LP's portfolio, making the stock its 19th largest holding. Two Seas Capital LP owned approximately 5.80% of Adaptimmune Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently added to or reduced their stakes in ADAP. Invesco Ltd. raised its stake in shares of Adaptimmune Therapeutics by 82.0% in the fourth quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company's stock worth $34,000 after purchasing an additional 28,526 shares during the last quarter. Two Sigma Advisers LP increased its holdings in Adaptimmune Therapeutics by 492.0% in the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company's stock worth $38,000 after buying an additional 58,787 shares in the last quarter. Two Sigma Investments LP lifted its stake in Adaptimmune Therapeutics by 33.5% during the 4th quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company's stock valued at $41,000 after acquiring an additional 19,146 shares during the period. Virtu Financial LLC lifted its stake in Adaptimmune Therapeutics by 21.5% during the 4th quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company's stock valued at $66,000 after acquiring an additional 21,688 shares during the period. Finally, LPL Financial LLC boosted its holdings in shares of Adaptimmune Therapeutics by 106.5% during the 4th quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company's stock valued at $99,000 after acquiring an additional 94,623 shares during the last quarter. 31.37% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on ADAP shares. HC Wainwright lowered their price objective on shares of Adaptimmune Therapeutics from $3.50 to $3.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Barclays lowered their price target on Adaptimmune Therapeutics from $1.00 to $0.46 and set an "underweight" rating on the stock in a report on Wednesday, May 14th. StockNews.com initiated coverage on Adaptimmune Therapeutics in a report on Friday, May 16th. They issued a "buy" rating for the company. Jones Trading cut Adaptimmune Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 11th. Finally, Scotiabank reduced their price target on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating for the company in a research report on Friday, March 21st. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $1.52.

Adaptimmune Therapeutics Trading Down 1.4%

Adaptimmune Therapeutics stock opened at $0.29 on Wednesday. The firm's 50 day moving average price is $0.28 and its 200-day moving average price is $0.50. Adaptimmune Therapeutics plc has a 1 year low of $0.20 and a 1 year high of $1.48. The stock has a market cap of $73.90 million, a P/E ratio of -1.31 and a beta of 2.86. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last announced its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.18). The firm had revenue of $7.29 million for the quarter, compared to analysts' expectations of $6.55 million. Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%. On average, equities analysts predict that Adaptimmune Therapeutics plc will post -0.14 earnings per share for the current fiscal year.

Adaptimmune Therapeutics Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.